Passage Bio Inc is a genetic medicines company... Show more
PASG's Aroon Indicator triggered a bullish signal on June 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 87 similar instances where the Aroon Indicator showed a similar pattern. In of the 87 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PASG advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .
PASG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for PASG moved out of overbought territory on June 05, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PASG as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PASG turned negative on June 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
PASG moved below its 50-day moving average on June 23, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PASG crossed bearishly below the 50-day moving average on June 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PASG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.446) is normal, around the industry mean (16.377). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). PASG's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.527).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PASG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PASG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options
Industry Biotechnology
A.I.dvisor indicates that over the last year, PASG has been loosely correlated with VYGR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PASG jumps, then VYGR could also see price increases.
Ticker / NAME | Correlation To PASG | 1D Price Change % | ||
---|---|---|---|---|
PASG | 100% | +0.33% | ||
VYGR - PASG | 34% Loosely correlated | -0.34% | ||
RAIN - PASG | 32% Poorly correlated | +5.79% | ||
ARWR - PASG | 31% Poorly correlated | +0.06% | ||
FBIO - PASG | 30% Poorly correlated | -1.62% | ||
ALEC - PASG | 30% Poorly correlated | -1.33% | ||
More |